{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-023860","form_type":"8-K","ticker":"BCTX","cik":"0001610820","company_name":"BriaCell Therapeutics Corp.","filed_at":"2024-06-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.247678+00:00","generated_at":"2026-06-01T04:20:12.016201+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"BriaPro subsidiary reports $317K net loss, $1 cash, going concern doubt","bullets":["Net loss of $316,517 for nine months ended April 30, 2024; zero revenue.","Cash and equivalents of $1; current liabilities $356,734; shareholders' deficit $301,924.","Going concern warning: dependent on future financing, significant doubt.","Intangible assets (patents) of $203,614 from August 2023 spin-out from BriaCell.","Operating loss of $366,960 for the nine-month period, R&D expense $227,249."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-023860","json":"https://secwatch.observer/filing/0001493152-24-023860.json","markdown":"https://secwatch.observer/filing/0001493152-24-023860.md","text":"https://secwatch.observer/filing/0001493152-24-023860.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1610820/000149315224023860/0001493152-24-023860-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1610820/000149315224023860/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T04:20:12.016201+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}